DEC 06, 2021 3:00 AM PST

Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment

WRITTEN BY: Katie Kokolus

The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer that grows in B cells, the immune cells that make antibodies to fight infection. Over 18,000 people are diagnosed with DLBCL in the United States each year.  

One subgroup of DLBCL is characterized by a genetic pattern described as “activated B cell-like” (ABC).  Tumors of the ABC subtype require chronic B cell receptor signaling, a function inhibited with a targeted therapy called ibrutinib.    

A new study published in Cancer Cell suggests that a targeted therapy called ibrutinib administered in combination with a standard chemotherapy regimen significantly benefits some DLBCL patients. Although DLBCL is most common in adults over 60 years, the study focused on patients under 60.  This cohort that demonstrated a survival benefit in a previous Phase III trial, the Phoenix Trial, investigating a similar combination therapy.  

All patients received standard R-CHOP chemotherapy consisting of rituximab, cyclophosphamide, hydroxydaunomycin (also known as doxorubicin), oncovin (also known as vincristine), and prednisone.  Patients received R-CHOP with or without ibrutinib. 

The researchers analyzed biopsies from patients on the Phoenix Trial and identified three genetic signatures, MCD, BN2, and N1, within the ABC tumor samples.  When evaluating the MCD and N1 subtypes, the analysis revealed 100% three-year event-free survival in patients under 60 treated with R-CHOP plus ibrutinib.  Patients exhibiting these tumor subtypes treated with R-CHOP alone had less than 50% three-year event-free survival. 

The exciting data presented in the study strongly promotes new personalized medicine strategies for specific patients with DLBCL.  While doctors typically run tests to classify the ABC subgroup, there is no commercial test available to further identify the MCD and N1 subtypes.  More personalized strategies may become feasible as we develop a greater understanding of the underlying mechanisms of combination R-CHOP plus ibrutinib therapy.  Subtyping tumors could help doctors and patients develop more effective personalized treatment strategies.  

 

Sources: DLBCL, B cells, ABC, ibrutinib, Cancer Cell, Phase III trial, R-CHOP

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
SEP 06, 2021
Drug Discovery & Development
Antibiotics Increase Colon Cancer Risk by 17%
SEP 06, 2021
Antibiotics Increase Colon Cancer Risk by 17%
People who take antibiotics are at an increased risk of developing colon cancer within five to ten years. The research w ...
NOV 08, 2021
Cancer
Genetic Explanation for Low Cancer Incidence in Elephants
NOV 08, 2021
Genetic Explanation for Low Cancer Incidence in Elephants
Elephants possess two qualities that might make one expect they are at high risk of developing cancer; they are large an ...
DEC 03, 2021
Drug Discovery & Development
FDA approves new imaging drug to make ovarian cancer tumors glow.
DEC 03, 2021
FDA approves new imaging drug to make ovarian cancer tumors glow.
Earlier this week, the United States Food and Drug Administration (FDA) announced its approval for a novel dru ...
DEC 18, 2021
Cell & Molecular Biology
How the HTLV-1 Virus Can Turn Immune Cells Cancerous
DEC 18, 2021
How the HTLV-1 Virus Can Turn Immune Cells Cancerous
In some cases, viruses have been linked to cancer. For example, HPV, which is now preventable with a vaccine, can lead t ...
JAN 07, 2022
Drug Discovery & Development
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
JAN 07, 2022
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial o ...
Loading Comments...